Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US PTO reissue strengthens Pfizer's Lipitor patent

This article was originally published in Scrip

Executive Summary

Pfizerhas completed an action to have the US Patent and Trademark Office reissue a patent related to its hypolipaemic, Lipitor. It will be referred to as reissue patent RE40667. The company applied for the reissue patent more than two years ago, in order to correct a technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form sold as Lipitor (expiring in June 2011).

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel